Marine Bioactive Compounds on Osteoporosis and Related Bone Diseases
A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Biomaterials of Marine Origin".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 9531
Special Issue Editor
Interests: regenerative medicine; bone; cartilage; drug delivery; controlled release; histology; histomorphometry; immunochemistry; gene silencing; leiomyomas biology; osteoporosis
Special Issue Information
Dear colleagues，
Marine Drugs invites you to submit contributions to this Special Issue on "Bioactive Marine Components on Osteoporosis and Related Bone Diseases."
Osteoporosis is a systemic skeletal disease characterized by a decrease in bone mass and a deterioration of bone microarchitecture. Produced by an imbalance in the homeostasis of the bone tissue, in which resorption exceeds osteosynthesis, osteoporosis is diagnosed in clinical practice using the criteria of bone mineral density (BMD) or the appearance of bone fracture fragility. According to the BMD criteria, osteoporosis is diagnosed by a BMD that is 2.5 standard deviations or more below the mean of a reference population of healthy young adult women. Osteoporosis results in increased bone fragility and the consequent cumulative risk of fracture. With a decreased BMD as the population ages around the world, osteoporosis has become more prevalent among the elderly, with the number of osteoporotic fractures increasing substantially and the risk of suffering an osetoporotic fracture being between 40% and 50% for women and between 13% and 22% for men in Western countries. The clinical management of the osteoporotic patient is based mainly on the use of antiresorptive drugs such as bisphosphonates and anabolics drugs such as teriparatide, or molecules that have both actions such as Domozumab. These treatments are relatively effective but have some undesirable effects. The condition of osteoporosis is also characterized by specific metabolic alterations that characterize other related bone diseases, such as osteomalacia, fibrocystic osteitis, or renal osteodystrophy. Current research is focused on two approaches: elucidating the pathogenic mechanisms underlying the development of osteoporosis and related bone diseases, and searching for new therapeutic agents to prevent or reverse the osteoporotic condition, reducing the risk of fragility fractures in the elderly population and thereby improving the quality of life of affected people.
This Special Issue aims to collect original in vitro and in vivo research articles on the role of marine compounds as potential therapeutic agents to prevent or treat osteoporosis and related bone diseases. Articles on the study of the mechanisms of action by which marine compounds modulate bone homeostasis through their action on osteoblasts and osteoclasts are also welcome. Reviews that summarize the potential effects of marine compounds on osteoporosis and related bone diseases are also welcome.
Dr. Ricardo Reyes Rodríguez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- osteoporosis
- osteoporosis animal models
- marine compounds
- osteoblast
- osteoclast
- collagen type I
- bone homeostasis
- fragility fracture
- drug delivery
- bone histomorphometry
